NCT02881138已完成1 期
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- maximal tolerance dose (MTD) of RC48-ADC
研究概览
简要总结
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form;
- •Aged 18-65 years;
- •ECOG physical condition is 0 or 1;
- •Life expectancy greater than 12 weeks;
- •Diagnosed with histologically or cytologically-confirmed, standard treatment is ineffective (disease progresses after treatment) or HER2-positive, locally advanced or metastatic malignant solid tumor patients who cannot tolerate standard therapy, cannot receive or do not have standard therapy;
- •Human epidermal growth factor receptor 2 (HER2)-positive as measured either by immunohistochemistry (IHC 2+ and by fluorescence in situ hybridization (FISH) or by immunohistochemistry (3+);
- •Patients with measurable and appreciable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1);
- •Adequate organ function as defined by the following criteria:
- •absolute neutrophil count(ANC) >= 1.5 x 10(9)/L;
- •platelets>=100*10(9)/L;
- •Total serum bilirubin <=1.5*ULN;
- •serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=2.5*upper limit of normal (ULN), or AST and ALT<=5*ULN with hepatic metastasis;
- •Serum creatinine clearance rate >=45ml/min;
- •international normalized ratio (INR) and activated partial thromboplastin time (APTT) must be less than or equal to 1.5 times the upper limit of the normal range (ULN);
- •Women of child-bearing potential and men must agree to use adequate contraception (e.g. condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 30 days after the last dose of study drug;
- •Left ventricular ejection fraction (LVEF) >= 50%.
排除标准
- •Current pregnancy or lactation;
- •Received anti-tumor treatment 4 weeks before study administration, including chemotherapy, radiotherapy, hormone therapy, biological therapy or immunotherapy, except the following: Gonadotropin-releasing hormone (GnRH) antagonistic therapy for prostate cancer and Hormone replacement therapy;
- •Major surgery within 4 weeks of first dose of study drug and not fully recovered;
- •Receiving palliative radiation therapy for bone metastases if administered <= 2 weeks prior to first study treatment;
- •Toxicity of previous anti-tumor treatment has not recovered to CTCAE [version 4.0] 0-1 (with exception of alopecia);
- •Participated in other clinical drug studies within 4 weeks;
- •Hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
- •According to the judgment of the investigator, a clinically significant active infection;
- •A history of immunodeficiency, including a positive HIV test, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
- •Uncontrollable systemic diseases including diabetes, hypertension, lung Fibrosis, acute lung disease, interstitial lung disease, etc.;
- •Congestive heart failure with grade 2 or higher (including grade 2) by the New York Institute of Cardiology (NYHA) of the United States in the history of diseases such as acute myocardial infarction, unstable angina, stroke, or transient ischemic attack within 6 months before enrollment;
- •Insufficient adherence to participate in this clinical study;
- •Treated with Herceptin (Trastuzumab) within 60 days before the trial;
- •Have received systemic steroid therapy for a long time ( short-term users who discontinue medication> 2 weeks can be selected);
- •Uncontrolled primary or metastatic tumor of brain;
- •Peripheral neuropathy with grade>= 2;
- •People with a history of mental illness that is difficult to control.
研究组 & 干预措施
RC48-ADC
Experimental
Participants will be allocated to one of the following dose groups: 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC48-ADC followed by 28 days of dose limited toxicity (DLT) observation period.
干预措施: RC48-ADC (Drug)
结局指标
主要结局
maximal tolerance dose (MTD) of RC48-ADC
时间窗: DLT will be evaluated on 28 days of observation period
Maximum-tolerated dose (MTD) was defined as the highest dose level at which no more than one of six patients experienced DLT during the DLT assessment window.
AEs
时间窗: Estimated 2 years
The drug safety was assessed by investigator(s) according to NCI-CTCAE v4.0
次要结局
- Cmax(Estimated 2 years)
- AUC(Estimated 2 years)
- Tmax(Estimated 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of RC48-ADC in Subjects With Advanced Breast CancerAdvanced Breast CancerNCT03052634RemeGen Co., Ltd.112
已完成
1 期
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid TumorsSolid TumorsNCT02881190RemeGen Co., Ltd.57
已完成
1 期
A Study of RC108-ADC in Subjects With Advanced Malignant Solid TumorsSolid TumorNCT04617314RemeGen Co., Ltd.67
已完成
1 期
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung CancerNon Small Cell Lung CancerNCT04311034RemeGen Co., Ltd.37
尚未招募
1 期
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNon-small Cell Lung CancerNCT05745740RemeGen Co., Ltd.26